Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: A prospective single-arm study

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 397-401

  Koie, T ^a   Ohyama, C ^a   Yamamoto, H ^a   Hatakeyama, S ^a   Yoneyama, T ^a   Hashimoto, Y ^a   Kamimura, N ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

high risk; luteinizing hormone releasing hormone agonist plus low dose estramustine phosphate; neoadjuvant therapy

Indexed keywords

ESTRAMUSTINE PHOSPHATE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANASTOMOSIS LEAKAGE; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; GLEASON SCORE; GYNECOMASTIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPERATION DURATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM INJURY; SIDE EFFECT; SURGICAL INFECTION; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRAMUSTINE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84869238770     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.29     Document Type: Article

References (32)

1. D'Amico AV, Whittington R, Malkowics SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcomes after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
2. Joniau S, Van Poppel V. Localized prostate cancer: can we better define who is at risk of unfavorable outcome? BJU Int 2008; 101: S5-S10.
3. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002; 167: 112-116. (Pubitemid 34024512)
4. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH et al. Randomized comparative study of 3 versus 8-months neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500-507.
5. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J et al. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791-794. (Pubitemid 36999557)
6. Schulman CC, Debruye FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38: 706-713.
7. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138-1142. (Pubitemid 38746819)
8. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007; 110: 1248-1254. (Pubitemid 47435595)
9. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180: 565-570. (Pubitemid 351942412)
10. Prayer-Galetti T, Saccot E, Psgano F, Gardiman M, Cisternino A, Betto G et al. Longterm follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 2007; 100: 274-280. (Pubitemid 47036554)
11. Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008; 179: 911-915.
12. Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L et al. Phase 1/ 2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010; 116: 1699-1708.
13. Eklov S, Nilsson S, Larson A, Björk P, Hartley-Asp B. Evidence for a non-estrogenic cytostatic effects of estramustine on human prostatic carcinoma cells in vivo. Prostate 1992; 20: 43-50.
14. Speicher LA, Laing N, Barone LR, Robbins JD, Seamon KB, Tew KD. Interaction of an estramustine photoaffinity analogue with cytoskeltal proteins in prostate carcinoma cells. Mol Pharmacol 1994; 46: 866-872. (Pubitemid 24364098)
15. Hoshi S, Yamaguchi O, Fujioka T, Arai Y, Tomita Y, Habuchi T et al. A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. Int J Clin Oncol 2006; 11: 303-308. (Pubitemid 44306214)
16. Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 2004; 11: 103-109. (Pubitemid 38270459)
17. Koie T, Okamoto T, Imanishi K, Sugiyama N, Suzuki Y, Mori K et al. Phase II trial of neoadjuvant LHRH plus estramustine for high risk prostate cancer followed by radical prostatectomy. J Urol 2010; 183 (Suppl 4): e258 (abstract 659).
18. Koie T, Yamamoto H, Hatakeyama S, Kudoh S, Yoneyama T, Hashimoto Y et al. Minimum incision endoscopic radical prostatectomy: clinical and oncological outcomes at a single institute. Eur J Surg Oncol 2011; 37: 805-810.
19. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason gradibg of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242. (Pubitemid 41232997)
20. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG et al. AJCC Cancer Staging Manual, 6th edn Springer-Verlag: New York, 2002.
21. Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol 2005; 23: 8186-8191. (Pubitemid 46211553)
22. Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009; 115: 784-791.
23. Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 2011; 186: 882-887.
24. Taplin ME, Montgomery RB, Logothetis C, Bubley GJ, Richie JP, Dalkin BL et al. Effect of neoadjuvant abiraterone acetate plus leuprolide acetate on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer: results of a randomized phase II study. J Clin Oncol 2012; 30 (Suppl) abstract 4521.
25. Van Poppel H, Werbrouck PW, Baert L. Effect of estramustine phosphate on free androgens: a comparative study of the effect on orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer. Acta Urol Belg 1990; 58: 89-95.
26. Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 2011; 185: 848-854.
27. Kraus S, Noar Z, Seger R. Gonodotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett 2006; 234: 109-123.
28. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocriol Metab 1992; 75: 207-212.
29. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgenindependent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 1994; 59: 51-55. (Pubitemid 24310948)
30. Janknegt RA, Boon TA, van de Beek C, Grob P. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997; 49: 411-420. (Pubitemid 27138685)
31. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-1193. (Pubitemid 43907319)
32. Peters N, Armstrong K. Racial differences in prostate cancer treatment outcomes: a systematic review. Cancer Nurs 2005; 28: 108-118. (Pubitemid 40489235)